Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.

Thoracic cancer - 1 Feb 2023

Kunishige Michihiro, Ichihara Seiya, Kadota Naoki, Okano Yoshio, Machida Hisanori, Hatakeyama Nobuo, Naruse Keishi, Shinohara Tsutomu, Takeuchi Eiji

Abstract excerpt

Lung cancer with complex epidermal growth factor receptor (EGFR) and CTNNB1 comutations is rare, and the efficacy of tyrosine kinase inhibitors (TKIs) is generally poor. Here, we encountered a lung cancer patient with complex EGFR (L858R and E709X) and CTNNB1 comutations who successfully responded to afatinib. A 78-year-old woman visited our hospital with a cough and bloody sputum that had worsened over the past...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta Catenin

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 36519636
DOI: 10.1111/1759-7714.14775
PMCID: PMC9891858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.PMID 36519636Read ↗

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib.Semantic proximity Read ↗

A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case ReportSemantic proximity Read ↗

Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.Semantic proximity Read ↗

Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations.Semantic proximity Read ↗

Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2.Semantic proximity Read ↗

Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.Semantic proximity Read ↗

Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.Semantic proximity Read ↗

A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.Semantic proximity Read ↗

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusionSemantic proximity Read ↗

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.Semantic proximity Read ↗

The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression.Semantic proximity Read ↗

Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.